Literature DB >> 15156435

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Paul G Ambrose1, Jack B Anon, Joel S Owen, Scott Van Wart, Mary Eileen McPhee, Sujata M Bhavnani, Marion Piedmonte, Ronald N Jones.   

Abstract

The relationship between drug exposure and the time course of antimicrobial effect at the primary infection site for acute maxillary sinusitis has not previously been explored. This single-center, open-label study quantified the time course of sinus sterilization, described gatifloxacin exposure at the infection site, and posed the hypothesis that the use of continuous and quantitative time-related end points may allow for better characterization of drug effect with fewer patients than traditional clinical trial approaches. Of the 12 enrolled patients, 10 were clinically evaluable, from whom 7 pathogens were isolated: 4 Streptococcus pneumoniae, 2 staphylococci, and 1 Enterobacter aerogenes. The median predicted 24-h area under the curve (AUC) in sinus aspirates and plasma samples was 54.7 mg x h/L and 30.1 mg x h/L, respectively. The median 24-h AUC ratio for sinus aspirates and plasma samples was 1.51 (range, 0.88-2.23). For patients infected with pneumococci, the median time to sinus sterilization was 50 h. The use of quantitative time-related end points may be useful in evaluating the efficacy of antimicrobial agents with fewer patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156435     DOI: 10.1086/420739

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.

Authors:  Christopher M Rubino; Lei Ma; Sujata M Bhavnani; Joan Korth-Bradley; John Speth; Evelyn Ellis-Grosse; Keith R Rodvold; Paul G Ambrose; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 5.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

6.  Canadian clinical practice guidelines for acute and chronic rhinosinusitis.

Authors:  Martin Desrosiers; Gerald A Evans; Paul K Keith; Erin D Wright; Alan Kaplan; Jacques Bouchard; Anthony Ciavarella; Patrick W Doyle; Amin R Javer; Eric S Leith; Atreyi Mukherji; R Robert Schellenberg; Peter Small; Ian J Witterick
Journal:  Allergy Asthma Clin Immunol       Date:  2011-02-10       Impact factor: 3.406

Review 7.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Antimicrobial resistance in Haemophilus influenzae.

Authors:  Stephen Tristram; Michael R Jacobs; Peter C Appelbaum
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

9.  Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis.

Authors:  Horacio Ariza; Ramon Rojas; Peter Johnson; Richard Gower; Alice Benson; Janet Herrington; Renee Perroncel; Peter Pertel
Journal:  BMC Ear Nose Throat Disord       Date:  2006-04-28

10.  Antimicrobial drug resistance, regulation, and research.

Authors:  Joshua P Metlay; John H Powers; Michael N Dudley; Keryn Christiansen; Roger G Finch
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.